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Abstract: Hepatitis B virus (HBV) infection is a prime cause of liver diseases such as 
hepatitis, cirrhosis and hepatocellular carcinoma. The current drugs clinically available are 
nucleot(s)ide analogues that inhibit viral reverse transcriptase activity. Most drugs of this 
class are reported to have viral resistance with breakthrough. Recent advances in methods 
for in silico virtual screening of chemical libraries, together with a better understanding of 
the resistance mechanisms of existing drugs have expedited the discovery and development 
of novel anti-viral drugs. This review summarizes the current status of knowledge about 
and viral resistance of HBV drugs, approaches for the development of novel drugs as well 
as new viral and host targets for future drugs. 
Keywords:  hepatitis B virus; antiviral agent; drug development; drug resistance; 
modeling; rational drug design 
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Abbreviations: cccDNA – covalently closed circular DNA; FDA – U.S. Food and Drug 
Administration; GASP – Genetic Algorithm Similarity Program; HBsAg – hepatitis B 
surface antigen; HBeAg – hepatitis B e antigen; HBV – hepatitis B virus; HBx – HBV X 
protein; HCC – hepatocellular carcinoma; HCV – Hepatitis C virus; HIV – human 
immunodeficiency virus; HNF – hepatocyte nuclear factor; RT – reverse transcriptase; 
WHO – World Health Organization; WHV – woodchuck hepatitis virus 
 
1. Introduction 
Hepatitis B virus (HBV), the prototype of the Hepadnaviridae family, is a small virus harboring 
only four open reading frames. The genome of HBV comprises a partially double-stranded 3.2-kb 
DNA. Chronic HBV infection is strongly associated with liver diseases like chronic hepatic 
insufficiency, cirrhosis, and hepatocellular carcinoma (HCC) [1-4]. The World Health Organization 
(WHO) estimates that there are currently 400 million individuals worldwide who are chronically 
infected with HBV, of whom 100 million eventually will die of chronic liver diseases or HCC [5,6]. 
Although vaccination and drugs against HBV have been introduced successfully, the level of global 
chronic infection still calls for development of new drugs for the control of HBV infection.   
Infection with HBV in hepatocytes results in the formation of covalently closed circular DNA 
(cccDNA) in the nucleus, which is the template transcribed to generate four major RNA species. HBV 
expresses four major viral antigens: precore/core, surface, polymerase and HBV X protein (HBx). 
Among these HBV-encoded proteins, viral polymerase is the key protein for genome replication and 
consists of terminal protein (following a spacer), reverse transcriptase (RT), and RNAse H domains. 
The RT domain is responsible for the minus strand DNA synthesis, the first step in HBV replication, 
from the pregenomic RNA template [7,8]. Therefore, RT is a fascinating target for anti-HBV drugs.   
All the clinically available HBV drugs are nucleotide or nucleoside analogues that target the 
activity of viral RT. All drugs approved as anti-HBV agents are reported to have viral resistance due to 
specific mutations in the RT domain, which encourage the development of novel anti-HBV agents 
targeting non-polymerase viral or host proteins. In this review we summarize the current status of anti-
HBV agents with their viral resistance and the novel small chemical anti-HBV agents targeting non-
polymerase proteins. 
2. Anti-HBV Drugs  
The currently available anti-HBV agents are all nucleotide or nucleoside analogues RT inhibitors. 
These are summarized in Table 1. 
2.1. Current anti-HBV drugs 
2.1.1. Lamivudine 
Lamivudine [(-)2′,3′-dideoxy-3′-thiacytidine, commonly called 3TC, Zeffix
®) was initially 
developed for the treatment of human immunodeficiency virus (HIV) infection. Lamivudine is a Molecules 2010, 15                
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synthetic nucleoside analogue, with activity against HBV and HIV. It is sequentially phosphorylated to 
lamivudine triphosphate by cellular kinases. After removal of the diphosphate group, lamivudine 5′-
monophosphate is incorporated into the growing viral DNA chain at the 3’-end by HBV polymerase. 
The incorporation of lamivudine into the viral DNA chain induces premature chain termination due to 
the absence of 3’-OH, which is essential for chain polymerization.   
Table 1. Approved anti-HBV drugs. 
Molecule Structure  Brand  name  Mechanism  Company  Year of FDA 
approval 
Lamivudine 
 
Zeffix, 
Heptovir, 
Epivir, and 
Epivir-HBV 
Nucleoside 
analogue/ 
RT Inhibitor 
GlaxoSmithKline 
1998 (for adults)
and 2000 (for 
children) in US
Adefovir 
 
Preveon and 
Hepsera 
Nucleotide 
analogue/ 
RT Inhibitor 
Gilead 2002  (US) 
Entecavir 
 
Baraclude 
Nucleoside 
analogue/ 
RT Inhibitor 
Bristol Meyers 
Squibb  2005 (US) 
Telbivudine 
 
Sebivo (Europe) 
Tyzeka (US) 
Nucleoside 
analogue/ 
RT Inhibitor 
Idenix, 
Novartis 
 
2006 (US) 
Clevudine 
 
Levovir and 
Revovir 
Nucleoside 
analogue/ 
RT Inhibitor. 
Bukwang Pharm  2006 (KOREA) 
Tenofovir 
 
Viread 
Nucleotide 
analogue/ 
RT Inhibitor 
Gilead 2008  (US) Molecules 2010, 15                
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In vitro antiviral activity of lamivudine against HBV was assessed in HBV DNA-transfected cells 
and IC50 values ranged between 0.01 μM and 3.3 μM, depending on the duration of exposure of cells to 
lamivudine, the cell model system, and the protocol used [9]. 
2.1.2. Adefovir Dipivoxil 
Adefovir dipivoxil (Hepsera
®,  9-[2-[[bis[(pivaloyloxy)methoxy]-phosphinyl]-methoxy]ethyl]-
adenine) is an acyclic nucleotide analog with activity against HBV. Adefovir was approved by the U.S. 
Food and Drug Administration (FDA) for use in the treatment of hepatitis B in September 2002 and by 
the European Union in March 2003. Because adefovir is an analog of adenosine monophosphate, it can 
be easily phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir 
diphosphate inhibits HBV DNA polymerase by competing with the natural substrate deoxyadenosine 
triphosphate. The incorporation of adefovir diphosphate into the growing viral DNA causes premature 
DNA chain termination similar to lamivudine [10]. The inhibition constant (Ki) for adefovir 
diphosphate for HBV DNA polymerase is 0.1 μM. In vitro antiviral activity of adefovir against HBV 
was assessed in HBV DNA-transfected human hepatoma cell lines and the IC50
 values ranged between 
0.2 μM and 6.3 μM depending on the assay conditions [9]. 
2.1.3. Entecavir   
Entecavir (Baraclude
®, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-
methylenecyclopentyl]-6H-purin-6-one monohydrate) is a guanosine nucleoside analogue with 
selective activity against HBV. Entecavir was approved by the U.S. FDA in March 2005 for the 
treatment of hepatitis B infection. Entecavir is a guanosine nucleoside analogue and is efficiently 
phosphorylated to the active triphosphate form. By competing with the natural substrate 
deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits the activities of HBV 
polymerase.  
Entecavir was more efficacious than other previous agents and had low side effects [11]. Entecavir 
inhibited HBV DNA synthesis by 50% at a concentration of 3.75 nM in in vitro assays [12]. 
Lamivudine-resistant HBV (rtL180M, rtM204V) was also susceptible to entecavir treatment with high 
efficacy in vitro [13]. Clinical trials revealed that entecavir was superior compared to lamivudine in 
vivo for both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients [14,15]. Chronic 
hepatitis B patients who were refractory to lamivudine treatments showed improved virologic and 
serology outcomes [16,17]. 
2.1.4. Telbivudine 
Telbivudine [Tyzeka
®, LdT, 1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil)] is a synthetic 
thymidine nucleoside analogue with activity against HBV. Telbivudine is the unmodified L-isomer of 
the naturally occurring nucleoside, thymidine; therefore, phosphorylation to the active telbivudine 
triphosphate form by cellular kinases is easily accomplished. The telbivudine 5'-triphosphate 
eventually inhibits HBV DNA polymerase by competing with the natural substrate, thymidine 5'-
triphosphate. Incorporation of telbivudine 5'-triphosphate into replicating HBV DNA causes premature Molecules 2010, 15                
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DNA chain termination. In vitro antiviral activity of telbivudine against HBV replication was assessed 
in HBV-stable cell line, hepG2 2.2.15 human hepatoma cells, and the IC50
 values were around 0.19 μM 
[18]. Telbivudine was not active against HIV-1 at concentrations of up to 100 μM in vitro. Clinical 
trials have shown that telbivudine is superior to lamivudine or adefovir in patients with chronic 
hepatitis B [19-21]. 
2.1.5. Clevudine   
Clevudine (Levovir
®,
 1-(2-deoxy-2-fluoro--arabinofuranosyl)thymine, also known as L-FMAU), 
is a pyrimidine analog  with potent antiviral activity against HBV [22]. Like other nucleoside 
analogues, clevudine inhibits HBV polymerase by competing with the natural substrate, thymidine. 
Clevudine has been approved in Korea and the Philippines for the treatment of chronic hepatitis B 
patients and is now under Phase 3 clinical studies in China. Clevudine inhibits the DNA-dependent 
DNA activity of HBV polymerase as well as reverse transcription and priming [23,24]. 
The in vitro antiviral activity of clevudine against HBV was assessed in HBV DNA-transfected 
human hepatoma cells and the IC50 value was 0.9 μM [9]. Phase III clinical trial results showed that 
clevudine therapy for 24 weeks has a potent and sustained antiviral effect in both HBeAg-positive and 
-negative chronic hepatitis B patients [25,26].   
2.1.6. Tenofovir   
Tenofovir disoproxil fumarate (Viread
®, 9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]-
phosphinyl]methoxy]propyl] adenine fumarate) is an acyclic nucleotide analog with activity in vitro 
against retroviruses, including HIV-1, HIV-2, and HBV. Tenofovir disoproxil fumarate is an orally 
bioavailable ester prodrug of tenofovir (also known as PMPA). Tenofovir is a methyl derivative of 
adefovir and shows a very similar mechanism of action and antiviral resistance pattern to adefovir. 
Therefore, like adefovir, tenofovir exhibits antiviral activity against lamivudine-resistant HBV in vivo 
and in vitro [27-29].   
Tenofovir was approved by the U.S. FDA in October 2001 for the treatment of HIV and in August 
2008 for the treatment of chronic hepatitis B. Like adefovir, tenofovir is rapidly metabolized 
intracellularly into the active metabolite, tenofovir diphosphate, by cellular kinases. Tenofovir 
diphosphate inhibits HBV DNA polymerase RT by competing with the natural substrate, 
deoxyadenosine triphosphate, causing the termination of the growing DNA chain since it lacks a 3' 
hydroxyl group. The Ki for viral DNA polymerase is 0.02 μM, 5-fold lower than the Ki of adefovir.   
In vitro antiviral activity of tenofovir against HBV replication was assessed using HBV-transfected 
human hepatoma cell lines and the IC50 value was 2.5 μM [9]. Phase III clinical trial results showed 
that tenofovir therapy for 48 weeks at a daily dose of 300 mg had superior antiviral efficacy with a 
similar safety profile compared with adefovir dipivoxil at a daily dose of 10 mg [30]. 
2.2. Adverse effects of current HBV drugs 
The major adverse effects of long-term administration of nucleotide or nucleoside RT inhibitors are 
nephrotoxicity and myopathy [31,32]. Nephrotoxicity is characterized by gradual increases in serum Molecules 2010, 15                
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creatinine and decreases in serum phosphorus due to the inhibition (or toxicity) of kidney function. 
Adefovir and tenofovir (structural analogue of adefovir) are reported to be associated with 
nephrotoxicity at higher doses in HIV-infected patients and in chronic hepatitis B patients [31,33,34]. 
In the case of adefovir, the FDA did not approve the drug due to concerns about the severity and 
frequency of kidney toxicity when dosed at 60 or 120 mg for the treatment of HIV infection [35]. 
However, Gilead Sciences continued its development for HBV treatment, for which it is effective at a 
much lower dose of 10 mg. Because the long-term administration of adefovir may increase the overall 
risk of nephrotoxicity, it is important to monitor renal function for all patients during treatment with 
adefovir and tenofovir. 
The major human DNA polymerases include DNA polymerases alpha, beta, gamma, delta and 
epsilon. Most of the nucleotide or nucleoside analogues are weak inhibitors of mammalian alpha-, 
beta-, and gamma-DNA polymerases [36]. This inhibition is likely related to drug-induced adverse 
effects. Among these, DNA polymerase gamma is located in mitochondria whereas other polymerases 
are found in the nucleus. The mitochondrial DNA polymerase gamma is reported to have both DNA- 
and RNA-dependent DNA polymerase activity similar to those of viruses such as HBV and HIV. The 
functional similarity between viral polymerase and mitochondrial DNA polymerase gamma is likely 
responsible for the nucleoside drug-induced toxicity. DNA polymerase gamma is reported to have 
higher affinity for nucleotide or nucleoside RT inhibitors. The incorporation of nucleoside inhibitors 
into the mitochondrial DNA induces premature genome termination, resulting in mitochondrial DNA 
deletions (see review by references [37,38]). 
Myopathy characterized by muscle pain, muscle weakness or muscle tenderness is observed in 
patients who have received long-term treatment of clevudine and telbivudine [38,39]. Seok et al. [39] 
reported that seven patients who received 8-13 months of clevudine therapy showed severe evidence of 
myopathy with elevated creatine kinase levels. Muscle biopsies and molecular studies showed that the 
myopathy is associated with the depletion of mitochondria DNA and myonecrosis, possibly due to the 
inhibition of polymerase gamma by clevudine. These findings indicate that long-term treatment with 
structurally similar telbivudine and clevudine (fluoro-telbivudine) may lead to mitochondrial toxicity-
mediated myopathy [32]. 
3. Viral Resistance to HBV Drugs 
3.1. Molecular mechanism of resistance  
Like other viral polymerases, the reverse transcriptase of HBV polymerase lacks proofreading 
activity on the newly synthesized viral genome, resulting in the introduction of random mutations into 
the progeny HBV DNA. The error rate of HBV polymerase is approximately 1 per 10
5 to 10
7 base 
synthesis due to the error-prone nature of HBV RT [40,41]. The HBV quasispecies produced by the 
infidelity of HBV RT could account for the emergence of the many natural mutants with point 
substitutions [42]. Under selection pressure from the host immune system or administration of antiviral 
agents, these quasispecies can converge into a dominant HBV mutant that can escape the selection 
pressure. The molecular mechanisms of resistance to nucleos(t)ide analogue drugs and the clinical 
importance of resistance for chronic hepatitis B have been comprehensively reviewed recently [43,44]. Molecules 2010, 15                
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The well established and documented escape mutants against long-term antiviral treatment are as 
follows.  
3.1.1. Lamivudine resistance 
The incidence of resistance during lamivudine treatment increases progressively at rates of 14 to 
32% annually, approaching 80% after 48 months of treatment [45]. Genotypic analysis of viral isolates 
obtained from patients who showed breakthrough of HBV replication while receiving lamivudine 
enabled the identification of the primary resistance mutations to lamivudine. The element for primary 
resistance to lamivudine was mapped to mutations in the YMDD motif, a common active site in 
reverse transcriptase, in the C domain of HBV Polymerase. The rtM204I and rtM204V mutations, 
resulting in YIDD and YVDD, respectively, have been identified as primary resistance elements to 
lamivudine treatment [46]. The YMDD mutation is usually accompanied by a compensatory mutation, 
rtL180M, which enhances the viral replication of replication-defective rtM204I/V mutants [47]. Other 
compensatory mutations, L80I/V and V173L, in combination with rtM204I/V with or without 
rtL180M have also been identified [48.49]. In vitro drug susceptibility assays showed that mutations 
that confer resistance to lamivudine decrease the drug sensitivity by 100- to 1000-fold. Lamivudine 
resistance does not confer cross-resistance to adefovir dipivoxil or tenofovir. The molecular 
mechanisms of drug resistance have been predicted based on the crystal structure and molecular 
modeling [50,51]. 
3.1.2. Adefovir Dipivoxil resistance 
The rate of HBV resistance to adefovir is less frequent compared to the resistance to lamivudine. 
After two years of adefovir monotherapy in patients with HBeAg-negative chronic hepatitis, 
approximately 2% of patients were reported to have drug resistance. However, the rate of resistance 
increased considerably to 30% after five years of adefovir monotherapy [52,53].  
Genotypic analysis has revealed that adefovir resistance is conferred by the substitution of 
threonine for asparagine at codon 236 (rtN236T) in the D domain, and alanine for threonone or valine 
at codon 181 (rtA181T/V) in the B domain of HBV polymerase RT [54]. In vitro drug susceptibility 
assays showed that the rtN236T mutation does not affect sensitivity to lamivudine, telbivudine and 
entecavir; however, rtA181T mutation decreased susceptibility to lamivudine (<10-fold), adefovir (2- 
to 8-fold) and tenofovir (2- to 3-fold) [55,56]. 
3.1.3. Entecavir resistance 
Entecavir is the most potent of the currently available anti-HBV agents. Resistance to entecavir was 
not reported in early clinical trials because the incidence of resistance in treatment-naïve patients was 
very low, less than 1% at 2 years [57]. Long-term monitoring of entecavir resistance has revealed that 
the resistance rate was only 1.2% even after five years of therapy in treatment-naïve patients [58]. 
However, when lamivudine-failure patients, who had lamivudine resistance, were treated with 
entecavir, the incidence of resistance to entecavir dramatically increased to 14% at two years and 51% 
at five years [58]. Molecules 2010, 15                
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The mutations associated with the primary resistance to entecavir are the most complex and have 
not been fully established in patients. Mutations in the viral polymerase associated with the emergence 
of entecavir resistance have been mapped to the B domain (rtI169T, rtL180M, rtS184G), C domain 
(rtM204I/V, rtS202I), and E domain (rtM250V). The lamivudine mutations, rtM204I/V with or 
without rtL180M, along with other mutations are frequently detected in patients who exhibit entecavir 
resistance [59]. In vitro cell-based drug susceptibility assays also showed that the presence of 
lamivudine-resistant mutations leads to several hundredfold increases in entecavir resistance. Entecavir 
resistance does not confer cross-resistance to adefovir dipivoxil and tenofovir [44]. 
3.1.4. Telbivudine resistance 
The cumulative frequency of genotypic resistance to telbivudine in HBeAg-positive patients at 52 
and 104 weeks was 5% and 25.1%, respectively, whereas, in HBeAg-negative patients, the resistance 
incidence was 2.2% and 10.8%, respectively [19,20]. The resistance rate at two years was lower than 
that of lamivudine (42%) and higher than those of adefovir (3%) and entecavir (<1%) [60].   
Genotypic analysis from telbivudine-treatment failure isolates showed that the rtM204I/V 
substitution was associated with virologic failure and rebound. The rtM204I substitution confers the 
primary resistance to telbivudine treatment and was frequently found with substitutions rtL80I/V and 
rtL180M.  In vitro drug susceptibility assays showed that rtM204I, rtL180M + rtM204V, 
rtI169T/rtM250V and rtT184G/rtS202I mutations exerted strong resistance to telbivudine treatment 
[61]. Because telbivudine is an L-nucleoside analogue, telbivudine resistance does not confer cross-
resistance to adefovir, tenofovir, and entecavir [62]. 
3.1.5. Clevudine resistance 
As an L-nucleoside analogue, clevudine (a fluorinated telbivudine) has a similar resistance profile 
to lamivudine and telbivudine. Because clevudine was approved very recently, long-term cumulative 
data on the incidence and genotypic mutations that cause clevudine resistance in chronic hepatitis B 
patients is not available.   
The rtM204I mutation was identified during week 32 of clevudine therapy in woodchuck HBV [63]. 
In vitro studies using site-directed mutagenesis have also demonstrated that clevudine is not active 
against HBV harboring a single rtM204I mutant [64,65]. Recently, Kwon et al. [9] identified several 
conserved mutations in RT domain during viral BT from four clevudine-failure patients, with rtM204I 
being the most common. In vitro phenotypic analysis showed that mutation rtM204I was 
predominantly associated with clevudine resistance, whereas rtL229V was a compensatory mutation 
for the impaired replication of the rtM204I mutant. They found that a quadruple mutant (rtL129M + 
rtV173L + rtM204I + rtH337N) conferred greater replicative ability and strong resistance to both 
clevudine and lamivudine. All of the clevudine-resistant clones were also lamivudine-resistant, but 
were susceptible to adefovir, entecavir, and tenofovir except for one mutant clone [9]. Molecules 2010, 15                
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3.1.6. Tenofovir resistance 
Tenofovir is an adefovir analogue, methyl adefovir, presenting a similar mechanism of action and 
characteristics to adefovir. Tenofovir was approved for chronic hepatitis B treatment very recently; 
therefore the resistance mutation and resistance rate of tenofovir has not been well studied yet.   
The substitution rtA194T, along with rtL180M + rtM204V, has been found in patients with HIV-
HBV co-infection who showed resistance to tenofovir treatment [66]. A recent in vitro drug 
susceptibility assay demonstrated that the rtA194T mutation is associated with partial tenofovir 
resistance (5- to7-fold increase), regardless of rtL180M + rtM204V mutation, and negatively impacts 
the replication competence of HBV constructs. Viral replication of rtA194T mutant can be restored to 
WT levels, if this mutation occurs together with precore or basic core promoter substitutions found in 
HBeAg-negative hepatitis B [67]. No genotypic substitutions in RT associated with phenotypic 
resistance to tenofovir were detected during 48-week treatment [30]. Limited in vivo and in vitro 
studies on the antiviral activity of tenofovir showed that lamivudine- and adefovir-resistant mutants are 
susceptible to tenofovir [9,28,29,62]. 
3.2. Molecular modeling study of drug-resistant HBV 
The currently available anti-HBV drugs show potent antiviral activity in patients with chronic 
hepatitis B; however, the resistance and cross-resistance to the drugs is a major obstacle in long-term 
treatment. Many studies have been conducted to understand the molecular basis of drug resistance, and 
the mechanistic characterization and molecular modeling of anti-HBV drugs complexed with HBV RT 
have been reported. Although the three-dimensional X-ray structure of HBV polymerase is not 
available, its homology model has been reported using the X-ray structure of HIV RT as a template 
[48,51,68-70]. Even though the homology models may not be accurate due to the low sequence 
homology between the overall HIV and HBV polymerase, the sequence conservation between the RT 
domains of HIV and HBV polymerase enables molecular modeling of HBV RT [71]. In particular, the 
residues around the active site that are responsible for recognizing the template-primer or an incoming 
nucleoside triphosphate are highly conserved. Nucleoside analogue HBV polymerase inhibitors cause 
chain termination after incorporation into the growing chain in the active site of HBV polymerase and 
consequently inhibit viral reverse transcriptase. Thus, the HBV homology model structure based on the 
crystal structure of HIV polymerase serves as a useful guide for understanding the molecular basis of 
HBV resistance to drugs.   
Molecular dynamics studies on the homology model structure of HBV can provide useful 
information regarding mutations associated with resistance to inhibitors of HBV polymerase.  
Daga  et al. [72] built a stereochemically significant homology model of HBV polymerase and 
suggested a significant role for conserved Lys 32 residue in HBV RT, which corresponds to Lys 65 in 
HIV RT, in binding of nucleotides and known HBV RT inhibitors. Their homology model of HBV 
polymerase had two main differences from previous reports: They aligned the sequence by using the 
proper match of a conserved Lys residue in HIV-1 RT, which has important salt bridge interactions 
with the γ-phosphate of the incoming nucleotide. Secondly, they used a different template structure of 
HIV-1 RT (PDB code: 1T05) that was a higher resolution crystal structure compared to the previously Molecules 2010, 15                
 
5887
used template (PDB code: 1RTD). Based on this modeling result, they provided an explanation for the 
various resistant mutants of HBV polymerase and successfully predicted binding conformations of 
known HBV inhibitors [72]. 
Das K et al. [51] constructed a three-dimensional homology model of the catalytic core of HBV 
polymerase based on the crystal structure of HIV-1 RT. Molecular modeling studies using the HBV 
polymerase homology model suggest that steric hindrance between the mutant amino acid side chain 
and lamivudine or emtricitabine, anti-HBV-drug, could account for the resistance phenotype. 
Specifically, steric conflict between the Ile or Val at position rt204 in HBV polymerase and the sulfur 
atom in the oxathiolane ring of lamivudine and emtricitabine is proposed to account for the resistance 
observed with rtM204I or rtM204V mutation. The effects of the rtL180M mutation, which also occurs 
near the HBV polymerase active site, appeared to be less direct, potentially involving rearrangement of 
the deoxynucleoside triphosphate-binding pocket residues. 
Sharon et al. [70] constructed a homology model structure of HBV polymerase, which is used for 
minimization, conformational search and induced fit docking followed by binding energy calculation 
for wild-type and mutant HBV polymerases (rtL180M, rtM204V, rtM204I, rtL180M + rtM204V, 
rtL180M + rtM204I). Their studies suggest a significant correlation between the fold resistance and the 
binding affinity of five anti-HBV agents: lamivudine, adefovir, entecavir, telbivudine and clevudine. 
Also, they analyzed different binding modes for synthetic nucleoside analogue drugs as well as natural 
nucleosides. Although their studies may not fully explain the difference of quantitative binding affinity, 
they showed detailed resistance mechanisms for anti-HBV drugs against wild-type and mutant HBV.   
Adefovir is active against wild-type and lamivudine-resistant strains of HBV [73]. In contrast to 
lamivudine therapy, adefovir is associated with delayed and uncommon selection of drug-resistant 
viruses [74]. Long-term treatment with adefovir dipivoxil leads to the rtN236T mutation, which 
displays reduced susceptibility to adefovir but remains sensitive to lamivudine [75]. Yadav V et al. 
[76] presented the molecular basis of the mechanism of adefovir-diphosphate against lamivudine-
resistant mutants and its decrease in susceptibility for rtN236T HBV polymerase mutants. These 
molecular dynamics studies demonstrated that the rtN236T HBV polymerase mutation does not affect 
the binding affinity of the natural substrate (dATP), but it decreases the binding affinity of adefovir-
diphosphate toward the rtN236T HBV polymerase. The lamivudine-resistant mutations, rtM204V and 
rtM204I, result in increased van der Waals contacts between adefovir-diphosphate and the mutated 
residues, which accounts for the better binding affinity of adefovir-diphosphate toward these mutants. 
The second lamivudine-related mutation, rtL180M, also results in increased van der Waals interactions 
between adefovir-diphosphate and the final residue of the primer strand, which accounts for the better 
binding affinity of adefovir-diphosphate in these mutants. 
Warner  et al. [48] determined the prevalence of rtL80V/I mutation in lamivudine-resistant HBV 
isolates and characterized the in vitro phenotype of the mutants. Although L80I increases sensitivity to 
lamivudine and imparts a replication defect, it enhances the in vitro replication of lamivudine-resistant 
(rtM204I) HBV. Molecular modeling revealed that Leu 80 does not interact directly with the enzyme’s 
substrates. Molecular models of HBV reverse transcriptase showed that, although Leu 80 is located 
distal to the enzyme’s dNTP binding pocket, substitution of isoleucine for leucine at this site partially 
restores replication efficiency by sufficiently changing the overall spatial alignment of other residues 
that are important for catalysis. These results imply that the presence of rtL80I decreases the enzyme’s Molecules 2010, 15                
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affinity for both dNTPs and lamivudine triphosphate and that the decrease in affinity for lamivudine 
triphosphate is greater than the decrease in affinity for the natural substrate, dCTP. 
As mentioned above, using the homology model structure of HBV polymerase, the amino acid 
changes resulting from mutations that give antiviral resistance can be mapped to functional regions to 
provide a better understanding of the molecular mechanism of resistance [51,71]. The HBV 
polymerase consists of four different domains: terminal protein, a space region, a catalytic RT domain 
and RNase H domain. We constructed and refined the model structure of HBV RT based on the 
homology to HIV-1 RT according to the reported method [72]. 
Figure 1. The ribbon diagram of homology model structure of HBV RT shows the location 
of the major mutations that confer resistance to clinically available six drugs. The HBV RT 
model structure was constructed and refined as previously reported [72]. HBV RT consists 
of three sub-domains: fingers (amino acid 1 to 49 and 90 to 172, in green), palm (amino 
acid 50 to 89 and 173 to 267, in cyan), and thumb (amino acid 268 to 351, in yellow). The 
locations of the mutations are indicated with the sphere model. 
dNTPBinding Site
Lamivudine Thumb
Palm
Finger
M204I/V
L80I/V
L180M/V
V173L
Mg
Mg
    
Adefovir
N236T
A181T/V
 
Entecavir
S184G
I169T
L180M
S202I
M204I/V
M250V
 
Telbivudine
A181T/V
L180M
L80I/V
M204I/V
 
 Molecules 2010, 15                
 
5889
Figure 1. Cont. 
Clevudine
L229V
V173L
M204I
H337N
L129M
 
Tenofovir
A194T
 
 
Figure 1 shows the location of the major mutations in RT that confer resistance to clinically 
available drugs. Detailed analysis of the model structure reveals that most of the drug-resistant 
mutations alter the conformation of at least one of the following sites: dNTP binding site, primer 
binding site, template binding site, dNTP incoming region, dNTP binding pocket, and magnesium ions 
binding site (highly conserved YMDD).   
4. Development of Anti-HBV Agents 
The development of antiviral agents is compelled by the need to overcome life-threatening viruses 
such as HIV. Recently, greater understanding of viral life cycles and more advanced development tools 
have enabled us to discover and develop novel antiviral agents faster and more easily. The strategies 
and rationale in the design of antiviral drugs have been comprehensively reviewed [10]. The anti-HBV 
drugs in clinical trials and HBV inhibitors of antigens or replication are summarized in Table 2 and 
discussed in the following. 
4.1. Drugs in clinical trials for HBV 
There are several new drug candidates that are in clinical trials for the treatment of chronic hepatitis 
B. Lagociclovir valactate (known as MIV-210), a prodrug of 3′-fluoro-2′,3′-dideoxyguanosine with 
high oral bioavailability in humans and potent activity against hepatitis B virus, is currently in phase 1 
and 2 clinical studies in Europe and Asia. MIV-210 is known to have activity against lamivudine-, 
adefovir-, and entecavir-resistant HBV variants. In the woodchuck model of HBV, treatment with 
MIV-210 at a dose of 20 mg/kg/day or 60 mg/kg/day was well tolerated and caused rapid and 
pronounced virological woodchuck hepatitis virus (WHV) DNA reduction as well as appreciable 
decreases in hepatic WHV cccDNA levels [77].   
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Table 2. Anti-HBV drugs in clinical trials. 
Molecule Structure  Brand 
name  Mechanism Company  Year 
Lagociclovir 
valactate  - 
Nucleoside 
analogue/ 
RT inhibitor/ 
Prodrug 
Medvir AB 
Phase II 
2005 
(Sweden) 
Elvucitabine  - 
Nucleoside 
analogue/ 
RT Inhibitor 
Achillion 
Pharmaceutic
als 
2001 (US) 
B-80380  - 
Nucleotide 
analogue/ 
RT Inhibitor 
LG Chem Ltd 
Phase II 
2003 
(KOREA)
radefovir  - 
Nucleotide 
analogue/ 
RT inhibitor/ 
Prodrug 
Metabasis 
Therapeutics 
Phase II 
2007 
(US) 
altorcitabine 
N
N
O
O
O
O
NH2
NH2
HO
H
 
Nucleoside 
analogue/ 
RT inhibitor/ 
Prodrug 
Idenix 
Pharmaceutic
als/Novartis 
Phase II 
2003 
(US) 
 
Elvucitabine [2',3'-dideoxy-2',3'-didehydro--L(-)-5-fluorocytidine] is a nucleoside analogue RT 
inhibitor developed by Achillion Pharmaceuticals. In vitro studies and several phase I/phase II clinical 
trials have demonstrated that elvucitabine has significant potency against HIV. It also showed strong 
anti-HBV activity for the treatment of chronic HBV [78]. In the initial Phase 2 clinical trial for HIV, Molecules 2010, 15                
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doses of 50 mg or greater per day were associated with an unacceptable reduction in patients’ white 
and red blood cells. Recently, the clinical trial was discontinued and the program was placed on hold 
while determination of the appropriate dosing regimen for elvucitabine was made for hepatitis B in  
the USA.   
LB-80380 is a nucleotide analogue RT inhibitor developed by LG Life Sciences, Ltd., in Korea for 
the treatment of HBV infection [79]. In vitro antiviral activity against wild-type and lamivudine-
resistant mutants (rtM204I/V, rtL180M + rtM204I/V) showed similar EC50 values to adefovir [80]. 
LB80380 is currently in phase 2 clinical studies for chronic HBV patients in South Korea. The results 
of the clinical study suggest that LB80380 at doses of up to 240 mg for a period of 12 weeks is safe, 
well tolerated, and effective at reducing viral load in chronic hepatitis B patients with lamivudine-
resistant virus [81,82]. 
Pradefovir, a selectively liver-activated prodrug of adefovir dipivoxil was developed by Metabasis 
Therapeutics. Pradefovir was developed to overcome the renal toxicity of adefovir dipivoxil and 
showed the delivery of adefovir and its metabolites to the liver with a 12-fold improvement in the 
liver/kidney ratio over adefovir dipivoxil [83]. 
Valtorcitabine, a well-absorbed prodrug of L-deoxycytidine, has also demonstrated potent 
suppression of serum HBV DNA in HBeAg-positive patients in a phase I/II study. Valtorcitabine was 
well-tolerated in all patient cohorts, with a safety profile comparable to that of placebo and synergistic 
with telbivudine for inhibiting HBV replication in vitro and in the woodchuck hepadnavirus  
model [84]. 
4.2. Novel non-nucleoside HBV inhibitors 
As described above, all currently available anti-HBV drugs are nucleoside or nucleotide analogues 
and inevitably associated with the development of HBV resistance to drugs because they inhibit the RT 
by competing with the natural dNTPs. Therefore, agents that can interfere with other targets in the 
viral life cycle are strongly needed for combination therapies, such as those used for the treatment of 
HIV. In this regard, many research groups are dedicated to developing non-nucleoside anti-HBV 
agents that exert different modes of action than nucleoside or nucleotide inhibitors. In this section, we 
divided the HBV inhibitors into two subgroups according to the mode of action: HBV inhibitors 
targeting viral antigens or replication. Table 3 summarizes the characteristics of non-nucleoside HBV 
inhibitors that target viral antigens.   
Zhang  et al. [85-87] synthesized a series of alisol A derivatives and evaluated their anti-HBV 
activities and cytotoxicities in vitro using lamivudine as a positive control. Their results demonstrate 
that simple modifications to the parent structure of alisol A resulted in inhibitory potency against 
secretion of hepatitis B surface antigen (HBsAg), such as compound 1 (Table 1). Ellagic acid isolated 
from Phyllanthus urinaria (compound 2) showed unique anti-HBV activities. Ellagic acid did not 
inhibit HBV replication or HBsAg secretion; rather, it blocked HBeAg secretion very effectively in 
HepG2 2.2.15 cells [88]. Compound 3 is a selective, potent inhibitor of secretion of both subviral and 
DNA-containing viral particles [89]. It did not affect the viral replication and HBeAg secretion. 
Further analysis showed that compound 3 is a specific inhibitor of HBsAg secretion. Although the 
exact mechanism of action of compound 3 remains to be elucidated, these observations suggest that its Molecules 2010, 15                
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effects occur through direct action on the HBV viral and subviral particles themselves, the antigens 
that they contain, or the cellular processes or factors that are uniquely required for the secretion of 
these particles. Su et al. [90] found that the natural pyranocoumarin derivatives (compound 4) 
suppressed the secretion of HBsAg in HepA2 cells and also showed cytotoxic activity against four 
human cancer cell lines (A549, MCF7, KB, and KB-VIN). The most interesting result in the 
cytotoxicity assay was that compound 4 showed significant activity only against KB-VIN cells, the 
multi-drug resistant cell line; on the other hand, they showed marginal or no activity against the other 
three cell lines.   
Table 3. Summary of non-nucleoside HBV inhibitors that target viral antigens. 
Compound 
(Target)  Structure Activity  Mechanism of 
Action  Reference 
1 
(HBsAg, 
HBeAg) 
CC50 : >2.6mM 
HBsAg(IC50): 
0.024 mM 
HBeAg(IC50): 
0.028 mM 
Inhibition of 
HBsAg and 
HBeAg secretion 
[85] 
2 
(HBeAg)  IC50: 0.07 μg/mL 
Inhibition of 
HBeAg secretion 
in HepG2 2.2.15 
cell line 
[88] 
3 
(HBsAg)  EC50: 1.5 μM  Inhibition of 
HBsAg secretion  [89] 
4 
(HBsAg)  EC50: 1.14 μM  Inhibition of 
HBsAg secretion  [90] 
5 
(Virion 
secretion) 
IC50: 0.12 μM 
Inhibition of the 
interaction 
between core and 
surface protein 
[91] 
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6 
(Virion 
secretion) 
IC50: 5.4 μM 
Inhibition of the 
interaction 
between core and 
surface protein 
[91] 
7 
(Capsid 
formation) 
N
H
N
N
F
F
Cl
F
O
O
IC50: 0.05 μM 
Inhibition of 
replication by 
nucleocapsid 
depletion 
[92] 
 
Using chemical library screening, Asif-Ullah et al. [91] identified compounds 5 and 6, which inhibit 
the interaction between the core protein and PreS region of the surface protein. These compounds 
prevented the production of HBV particles from transiently HBV-producing HuH7 cells. The IC50 
values of these compounds for inhibition of HBV production in HuH7 cells were 0.12 and 5.4 μM for 
compound 5 and compound 6, respectively. Although these compounds showed promising anti-HBV 
activity, the detailed mechanism of how the compounds interfere with the surface and core protein 
interactions requires further investigation. 
Compound 7 inhibits HBV nucleocapsid maturation leading to potent in vitro and in vivo antiviral 
activity [92]. It displayed a highly specific antiviral principle, namely, inhibition of capsid formation, 
concomitant with a reduced half-life of the core protein. This compound may become a valuable 
addition to future therapy in light of its specific mechanism of action. In vitro cell studies as well as 
HBV transgenic mice models showed a suitable preclinical pharmacokinetic and toxicology profile 
with high efficacy. 
The characteristics of non-nucleoside HBV inhibitors targeting viral replication are summarized in 
Table 4. The phenylpropenamide derivatives are potent inhibitors of in vitro HBV replication in stably 
or transiently transfected HepG2 cells [93,94]. These compounds showed no significant differences in 
sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + 
rtM204V) HBV. Although the mechanism of action of compound 8 is not clearly understood, it 
appears to be independent of interference with the RNA- or DNA-dependent activities of the HBV 
polymerase. Recently, Feld and colleagues found that compound 8 decreased the amount of RNA-
containing cytoplasmic HBV core particles, suggesting that this compound blocks HBV replication at 
the level of viral RNA packaging [95].   
A series of non-nucleoside ethyl 6-hydroxyquinoline-3-carboxylate  derivatives (compound 9 in 
Table 4) were synthesized and evaluated for anti-HBV activity in HepG2.2.15 cells [96]. Compound 9 
derivatives inhibited the expression of viral antigens HBsAg or HBeAg at low concentration and 
displayed excellent intracellular inhibitory activity and selectivity towards the replication of HBV Molecules 2010, 15                
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DNA. Of these ethyl 6-hydroxyquinoline-3-carboxylate derivatives, compound 9 was the most potent 
and highly specific inhibitor of HBV DNA replication in cell culture.   
Table 4. Summary of non-nucleoside HBV inhibitors that target viral replication. 
Compound Structure Activity  Mechanism of 
Action  Reference 
8  IC50: 2.4 μM in 
HepG2 cells 
Inhibition of 
replication by 
blocking RNA 
packaging 
[93-95] 
9 
IC50: 4.7 μM 
(Replication)  
IC50: 26.2 μM 
(HBsAg) 
IC50: 98.1 μM 
(HBeAg) in 
HepG2 2.2.15 
cells 
Inhibition of 
replication, HBsAg 
and HBeAg 
secretion 
[96] 
10 
O
O
O
O
NH
O
IC50: 0.08 μM in 
HepG2 2.2.15 
cells 
Inhibition of 
replication by 
down-regulation of 
HNF-3 and 4 
[97,98] 
11 
IC50: 0.9 μM 
in HepG2 cells 
CC50: >1000 μM 
Inhibition of 
replication  [99] 
12 
IC50: 0.7 μM 
CC50: 192 μM in 
HepG2 2.2.15 
cells 
Inhibition of 
replication  [100] 
13 
IC50: 0.206 μM 
CC50: >109.6 μM 
in HepG2 cells 
Inhibition of 
replication  [101] 
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14 
IC50: 0.25 μM 
in HepG2 2.2.15 
cells 
Inhibition of 
replication  [102] 
15 
IC50: 3.59 μg/mL 
in HepG2 2.2.15 
cells 
Inhibition of 
replication  [103] 
16 
IC50: 1.40 μM 
in HepG2 2.2.15 
cells 
Inhibition of 
replication, HBsAg 
and HBeAg 
secretion 
[104] 
17 
EC50: 0.12 μM 
in HepG2 2.2.15 
cells 
Inhibition of 
replication  [105] 
18  IC50: 1.52 μg/mL 
in HepG2 2.2.15 
Inhibition of 
replication   [106] 
19 
IC50: 0.57 μg/mL 
in DHBV 
replication. 
IC50: 4.0 μg/mL 
(HBsAg, HBeAg) 
Inhibition of 
replication, HBsAg 
and HBeAg 
secretion 
[107] 
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20 
IC50: 2.3 μM 
(HBsAg) 
IC50: 0.5 μM 
(replication)  
Inhibition of 
replication and 
HBsAg secretion 
[108] 
21 
 
EC50: 1.7 μM, 
CC50: 286 μM in 
HepG2 2.2.15 
cells 
Inhibition of virion 
secretion and 
replication 
[109] 
22 
 
IC50: ~0.01 μg/mL Inhibition  of  RT  [110] 
23 
 
IC50:0.08 μM in 
HepG2 2.2.15 
Inhibition of 
replication   [111] 
 
Helioxanthin and its derivative 5-4-2 (compound 10), a novel class of compounds, were reported to 
have potent anti-HBV activities in HepG2.2.15 cells, with EC50s of 1 and 0.08 μM, respectively [97]. 
The lamivudine-resistant rtL180M/M204V double mutant HBV strain was also sensitive to 
helioxanthin and compound 10. This class of compounds not only inhibited HBV DNA, but also 
decreased HBV mRNA and core protein expression. A recent study has demonstrated that compound 
10 suppresses HBV replication by post-transcriptional down-regulation of critical transcription factors, 
which are essential for HBV gene expression, hepatocyte nuclear factor (HNF) 4 and 3 [98]. 
Compound 10 was a potential novel anti-HBV agent that possesses a different mechanism of action 
from existing therapeutic drugs.   
Compounds 11 ~ 23 in Table 4 and their derivatives were synthesized and evaluated for their anti-
HBV activity and cytotoxicity in vitro (see references in Table 4). All compounds exhibited strong 
activity against HBV replication with low cytotoxicity in vitro. However, the stages of the viral life 
cycle or the targets involved in their mechanisms of action have not been determined. Further studies 
on the mechanisms of action and preclinical evaluations using animal models are therefore needed to 
describe this novel class of anti-HBV drug candidates. Molecules 2010, 15                
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4.3. Virtual screening, modeling and rational drug design 
Virtual screening is an efficient method for identifying drug candidates in silico from large chemical 
compound databases. Virtual screening, particularly receptor-based or ligand-based virtual screening, 
has emerged as a reliable, inexpensive method for identifying lead compounds. Advances in 
computational techniques have enabled virtual screening to be a powerful tool in the drug discovery 
process. Its usefulness has been verified by current applications in which hit and lead identifications 
against various disease targets were successfully retrieved (reviewed in reference [112]). There have 
been great advances in molecular modeling techniques that have resulted in the excavation of a large 
number of potential therapeutic drugs that are relevant to biological functions. The growth in the 
number of potential target molecules has increased the demand for reliable target validation as well as 
for technologies that can rapidly identify optimal lead candidates.   
Antiviral compounds have also recently been successfully identified by virtual screening. Many 
laboratories have investigated inhibitors of HIV-1 and Hepatitis C virus (HCV) using various targets 
and virtual screening methods [113-118]. Applications and examples of pharmacophore-based antiviral 
drug design are comprehensively reviewed recently [112].   
However, unfortunately, there has been no report of an HBV inhibitor study by virtual screening 
methods. This may partly be due to the lack of an X-ray crystal structure of HBV polymerase, which is 
needed to obtain reliable virtual screening results. Recently, a pharmacophore model of the synthesized 
compounds was proposed by the genetic algorithm similarity program (GASP) program [119] to give 
useful information for further structural modification [101]. Lv and colleagues synthesized the  
2-pyridone derivatives and tested for their in vitro anti-HBV activity [101]. Because the target of  
2-pyridone derivatives is unknown, the construction a pharmacophore model would be useful for 
further structural optimization and could also be used in virtual screening and for identifying new  
lead structures.   
The refined homology model structure of HBV based on the crystal structure of HIV-1 RT has 
successfully demonstrated the molecular mechanism of drug resistance to corresponding drugs [120]. 
The homology models provide mechanistic insight into HBV resistance that is consistent with the 
biological studies, although it still lacks the validation of direct structural data. Until the 3D structure 
of HBV polymerase is defined, the homology model structure will serve as a useful tool for better 
understanding the molecular mechanism of replication and resistance and for the investigation of anti-
HBV lead compounds.   
4.4. Targets for future drugs  
As described earlier, all current anti-HBV drugs are RT inhibitors of nucleoside or nucleotide 
analogues, leading to a high possibility of developing drug-resistant HBV. Treatment with multiple 
drugs having different mechanisms of action is therefore needed to improve viral clearance and 
prevent resistance. Thus, small molecule inhibitors that target the viral life cycle proteins other than 
polymerase are strongly needed for combination therapy.   
RT inhibitors suppress viral replication very efficiently but do not eliminate the existing virus and 
cccDNA. If the episomal cccDNA in hepatocytes is not eliminated, HBV can rebound if the conditions Molecules 2010, 15                
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are suitable for virion production. Recently, a fundamental understanding of the regulation of cccDNA 
has been elucidated by some groups [121-124]. The main features of their findings on cccDNA 
regulation are the involvement of HBx and the epigenetic control of cccDNA-bound histones and 
cccDNA itself. These efforts will allow development of future drugs that can control the biogenesis 
and regulation of cccDNA, the ultimate goal of HBV eradication.   
The inhibitors that have been reported to exert specific and potent anti-HBV activity with  
non-polymerase viral targets in vivo and in vitro warrant further evaluation in clinical trials. Small 
molecule inhibitors such as compound 7 (in Table 3) and compound 8 (in Table 4) efficiently block the 
nucleocapsid maturation [92] and pregenomicRNA encapsidation [93-95], respectively. HBV entry 
inhibitors that utilized the pre-S1 peptides, which are essential for virus entry into the hepatocytes, 
successfully prevent viral infection [125]. Introduction of intact or modified small-interfering RNA 
produces strong and persistent anti-HBV activity in vivo and in vitro [126-128]. The chemical 
inhibitors (compounds 5 and 6 in Table 3), which block the interaction between core and surface 
protein, exert strong anti-HBV activity [91]. The inhibition of this interaction will eventually block the 
maturation of virion assembly and virion secretion. Along with these inhibitors, materials that can 
block viral and host targets that are essential for HBV life cycle, such as HBx [129], HNF [98] and 
unidentified HBV receptor(s) [130], are candidates for future drugs against HBV.   
5. Conclusions 
Treatment for chronic hepatitis B patients depends on anti-HBV drugs. Even though the currently 
approved anti-HBV drugs, nucleos(t)ide analogues, show potent and fast antiviral response, several 
problems remain to be solved. These include the development of resistance and the side effects such as 
myopathy, which is induced by mitochondrial damage. Based on advances in the development of 
antiviral agents along with newly discovered drug candidates and combination therapy, resistance 
should not be a great concern in the near future. However, combination therapy for effective control of 
HBV requires the development of novel drugs that have different mechanisms of action.   
The mitochondrial damage is mainly due to the high affinity of nucleos(t)ide RT inhibitors for 
mitochondrial DNA polymerase gamma. Therefore, alleviation of side effects should be considered in 
the development of future nucleos(t)ide drugs. In this regard, the fine crystal structure of polymerase 
gamma was reported recently [131,132]. The elucidation of the polymerase gamma structure 
establishes a foundation for understanding the molecular basis of the toxicity of anti-retroviral drugs 
targeting HBV and HIV and the cause of cellular toxicity induced by some antiviral nucleoside 
analogs. Eventually, these fundamental studies in conjunction with advanced drug development tools 
will provide valuable information for the development of novel drugs without side effects. 
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